ClinicalTrials.gg
CompletedNCT02038036RESPONSE-2Updated Jul 20, 2021Results posted

Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.

A Phase 3 interventional study of Best Available Therapy and Ruxolitinib in Polycythemia Vera, sponsored by Novartis Pharmaceuticals. Completed at 48 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-20.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
149
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies testing ruxolitinib in Polycythemia Vera — 5 open to participants now, 8 under way, 1 of them phase 3. ruxolitinib · Polycythemia Vera.

Enrollment
7th of 17
149 · median 110
Started
2014
with 1 other
Phase 3
5 of 17
1 open now
Registered
7th of 17
by date
Lead sponsor
3 of 17
Novartis Pharmaceuticals

Among the 17 studies testing ruxolitinib in Polycythemia Vera, this one is the 7th largest by enrollment, is one of 2 that started in 2014, is one of 5 in phase 3, and was the 7th registered.

Polycythemia Vera

279 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.

Browse Polycythemia Vera studies →

Open to participants now

5 of the 17 studies testing ruxolitinib in Polycythemia Vera are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing ruxolitinib in Polycythemia Vera, or all of them as a file.
02

Study summary

This study compared the efficacy and safety of ruxolitinib to Best Available Therapy (BAT) in patients with polycythemia vera (PV) who were hydroxyurea (HU) resistant or intolerant and did not have a palpable spleen.

Read the detailed description

This was a prospective, multi-center, open-label, randomized, Phase IIIb study evaluating efficacy and safety of ruxolitinib versus BAT as selected by the Investigator in patients with PV who are resistant to, or intolerant of HU.

The study comprised of the following periods:

Screening Period (up to 5 weeks: Day -35 to Day -1): Screening evaluations were performed at one or more clinic visits, and reviewed to determine eligibility before the patient was randomized in the study.

Core Treatment Period (Day 1 to Week 80):

Patients were randomized in 1:1 ratio to either treatment group (ruxolitinib or BAT) and were to be treated with their randomized treatment.

Crossover Treatment Period (Week 28 or after) for BAT patients only:

Patients randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib. Patients crossing over on or after Week 28 had to complete all assessments for the End of Treatment (EoT) visit of the Core Treatment Period followed by the assessments in Cross-over visit evaluation schedule.

Extended Treatment Period (Week 80 to Week 260):

Patients receiving ruxolitinib at Week 80 (including patients who have crossed over from BAT) were eligible to continue up to Week 260 in the Extended Treatment Period. Patients continued the ruxolitinib dose that they received at Week 80. Patients who received BAT at Week 80 were not eligible to enter the Extended Treatment Period and had to have the EoT visit at Week 80 and an End of study (EoS) visit 30 days after the EoT visit.

Follow-up Period:

Patients were followed for safety during 30 days after the last dose of study drug and EoS visit assessments were performed post 30 days after the last dose of study drug. Patients who completed EoT (Week 80 for patients who received BAT, Week 260 for patients who received ruxolitinib or from the time of premature discontinuation) were to be followed-up for every 3 months for survival till the end of the study.

03

Conditions studied

  • Polycythemia Vera

Keywords

  • Polycythemia Vera
  • Hematologic Diseases
  • Myeloproliferative Disorders
  • Bone Marrow Diseases
  • Hydroxyurea
  • INC424
  • Ruxolitinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Confirmed diagnosis of PV according to the 2008 World Health Organization criteria, Non-palpable spleen, Phlebotomy dependent, Resistant to or intolerant of hydroxyurea, performance status of 0, 1 or 2.

Exclusion criteria

Exclusion Criteria:

Inadequate liver or renal function, Significant bacterial, fungal, parasitic, or viral infection requiring treatment, Active within the past 5 years, excluding specific skin cancers, Previously received treatment with a JAK inhibitor, Being treated with any agent, Women who are pregnant or nursing.

Other inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
149 participants (actual)

Study arms

  • Experimental
    Ruxolitinib

    Ruxolitinib was administered at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.

    Drug: Ruxolitinib

  • Active comparator
    Best Available Therapy (BAT)

    Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib.

    Drug: Best Available Therapy

Interventions

  • DrugBest Available Therapy

    Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib.

    Also known as: BAT

  • Ruxolitinib was administered at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.

    Also known as: INC424

06

What researchers measure

Primary outcomes

  1. Number of Participants Achieving Hematocrit (Hct) Control at Week 28

    Proportion of patients achieving Hct control at Week 28 was defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 28, with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8. Phlebotomy eligibility was defined by: * Confirmed Hct \> 45% that is at least 3 percentage points higher than the Hct obtained at Baseline Or * Confirmed Hct \> 48% The confirmation occurred 2 to 14 days subsequent to the initial observation.

    Time frame: Week 28

Secondary outcomes

  1. Number of Participants Achieving a Complete Hematological Remission at Week 28

    Proportion of patients achieving a complete hematological remission at Week 28 was defined by: * Hct control at Week 28 defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 28, with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and * WBC \< 10 x109/L at Week 28, and * Platelets ≤ 400 x 109/L at Week 28

    Time frame: Week 28

  2. Number of Participants Achieving a Hematocrit (Hct) Control at Week 52 and Week 80

    Proportion of patients achieving a Hct control at Week 52 was defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 52, and no more than one phlebotomy eligibility occurring post randomization and prior to Week 8 - Endpoint for Week 80 was defined, similarly.

    Time frame: Week 52 and 80

  3. Number of Participants Achieving a Complete Hematological Remission at Week 52 and Week 80

    Proportion of patients achieving a complete hematological remission at Week 52, was defined by: * Hct control at Week 52, as defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 52 with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and * White Blood Count (WBC) \< 10 x10\^9/L at Week 52, and * Platelets ≤ 400 x 10\^9/L at Week 52 * Endpoint for Week 80 was defined, similarly.

    Time frame: Week 52 and 80

  4. Number of Participants With Phlebotomies Over Time

    Phlebotomy eligibility was defined by Confirmed Hct \> 45% that is at least 3 percentage points higher than the Hct obtained at Baseline Or Confirmed Hct \> 48%. The confirmation occurred 2 to 14 days subsequent to the initial observation.

    Time frame: Baseline to Week 260

  5. Change From Baseline in Hematocrit (Hct) at Each Visit

    Hematocrit is the volume percentage of red blood cells (RBC) in the blood.

    Time frame: Baseline, Week 4, 8, 12, 16, 20, 24, 28, 40, 52, 66, 80, 92, 104, 117, 130, 143, 156, 169, 182, 195, 208, 221, 234, 247 and 260

  6. Change From Baseline in Hematocrit (Hct) at Each Scheduled Visit After Crossover in Participants Randomized to BAT Who Cross Over to Ruxolitinib

    Hematocrit is the percentage of red blood cells (RBC) in the blood.

    Time frame: Baseline (last assessment before cross over), Week 4, 8, 12, 16, 20, 24, 28, 40, 52, 64, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206, 219 and 232 after cross-over

  7. Spleen Length by Visit

    Spleen length was assessed by manual palpation at every study visit.

    Time frame: Week 4, 8, 12, 16, 20, 24, 28, 40, 52, 66, 80, 92, 104, 117, 130, 143, 156, 169, 182, 195, 208, 221, 234, 247 and 260

  8. Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status to Week 28

    The ECOG scale of performance status described the level of functioning of participants in terms of their ability to care for themselves, daily activity, and physical ability. The ECOG performance was recorded as per ECOG performance status grades ranging from 0 (fully active, able to carry on all pre-disease performance without restriction) to 5 (dead).

    Time frame: Baseline and Week 28

  9. Number of Participants Achieving a Partial Remission Based on the European Leukemia Net (ELN) and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Criteria at Week 28

    Proportion of patients achieving a partial remission at Week 28, based on the ELN and IWG-MRT criteria, as defined by: * Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) score reduction of greater than or equal to 10 points from baseline to Week 28, and * Hct control defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 28, with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and * WBC \< 10 x10\^9/L at Week 28, and * Platelets ≤ 400 x 10\^9/L at Week 28, and * No palpable spleen at Week 28, and * No hemorrhagic or thrombotic events, and * No transformation into post-PV myelofibrosis, myelodysplastic syndrome (IWG-MRT criteria) or acute leukemia (WHO criteria).

    Time frame: Week 28

  10. Number of Participants Who Achieved Partial Remission Based on the European Leukemia Net (ELN) and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Criteria at Week 52 and Week 80

    Proportion of patients who achieved partial remission at Week 52 based on the ELN and IWG-MRT criteria, as defined by: * MPN-SAF TSS score reduction of greater than or equal to 10 points from baseline to Week 52 and * Hct control defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 52 with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and * WBC \< 10 x109/L at Week 52 and * Platelets ≤ 400 x 109/L at Week 52 and * No palpable spleen at Week 52 and * No hemorrhagic or thrombotic events, and * No transformation into post-PV myelofibrosis, myelodysplastic syndrome (IWG-MRT criteria) or acute leukemia (WHO criteria). * Endpoint for Week 80 was defined, similarly.

    Time frame: Week 52 and 80

  11. Number of Participants Achieving a Hematocrit (Hct) Control at Week 104, Week 156, Week 208 and Week 260.

    Proportion of patients achieving a Hct control at Week 104 as defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 104 and with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8 Endpoint for Week 156, Week 208 and Week 260 were defined, similarly.

    Time frame: From Week 8 to Week 104, 156, 208 and 260

  12. Number of Participants Achieving a Complete Hematological Remission at Week 104, Week 156, Week 208 and Week 260

    Proportion of patients achieving a complete hematological remission at Week 104 as defined by Hct control defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 104, with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and * WBC \< 10 x10\^9/L at Week 104, and * Platelets ≤ 400 x 10\^9/L at Week 104 Endpoint for Week 156, Week 208 and Week 260 were defined, similarly.

    Time frame: From Week 8 to Week 104, 156, 208 and 260

  13. Number of Participants Who Achieved Partial Remission Based on the European Leukemia Net (ELN) and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Criteria at Week 104, Week 156, Week 208 and Week 260.

    Proportion of patients who achieved partial remission at Week 104, based on the ELN and IWG-MRT criteria, as defined by: * MPN-SAF TSS score reduction of greater than or equal to 10 points from baseline to Week 104, and * Hct control defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 104, with no more than one phlebotomy eligibility occurring post-randomization and prior to Week 8, and * WBC \< 10 x10\^9/L at Week 104, and * Platelets ≤ 400 x 10\^9/L at Week 104, and * No palpable spleen at Week 104, and * No hemorrhagic or thrombotic events, and * No transformation into post-PV myelofibrosis, myelodysplastic syndrome (IWG-MRT criteria) or acute leukemia (WHO criteria) Endpoint for Week 156, Week 208 and Week 260 are defined, similarly.

    Time frame: From Week 8 to Week 104, 156, 208 and 260

  14. Number of Participants With Transformation Free Survival Events

    Transformation-free survival is defined as one of the following: 1. Myelofibrosis (MF) as evidenced by bone marrow biopsy, or 2. Acute leukemia as evidenced by bone marrow blast counts of at least 20%, or peripheral blast counts of at least 20% lasting at least 2 weeks. 3. Death due to any cause during treatment period

    Time frame: Week 260 (ruxolitinib arm) and Week 80 (BAT arm)

  15. Number of Participants With Overall Survival (OS) Events

    Overall survival (OS) event is defined as death due to any cause. OS events were counted in the BAT arm, irrespective of whether participants crossed over to receive ruxolitinib when the event occurred.

    Time frame: up to Week 260

  16. Change From Baseline in Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)

    The MPN-SAF TSS is a disease specific questionnaire comprised of 10 items that measures fatigue related to MPN disease and the severity of nine of the most prevalent associated symptoms. Each item is scored on a scale ranging from 0 (no fatigue/absent) to 10 (As bad as you can imagine/worst imaginable).The MPN-SAF TSS is computed as the average of the observed items multiplied by 10 to achieve a 0-to-100 scale. The MPN-SAF TSS thus has a possible score range of 0 to 100 where a decrease indicates improvement.

    Time frame: Baseline, Week 4, 8, 16, 28, 40, 52, 80, 92, 104, 117, 130, 143, 156, 169, 182, 195, 208, 221, 234 and 247

  17. Change From Baseline in Total Scores of MPN-SAF by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover

    The MPN-SAF TSS is a disease specific questionnaire comprised of 10 items that measures fatigue related to MPN disease and the severity of nine of the most prevalent associated symptoms. Each item is scored on a scale ranging from 0 (no fatigue/absent) to 10 (As bad as you can imagine/worst imaginable).The MPN-SAF TSS is computed as the average of the observed items multiplied by 10 to achieve a 0-to-100 scale. The MPN-SAF TSS thus has a possible score range of 0 to 100 where a decrease indicates improvement.

    Time frame: Baseline (last assessment before cross over), Week 4, 8, 16, 24, 28, 40, 52, 92, 104, 117, 130, 143, 156, 169, 182, 195, 208, 221, 234 and 247 after cross-over

  18. Change From Baseline in Score as Per European Quality of Life 5-Dimension 5-level (EQ-5D-5L) Questionnaire

    EQ-5D-5L is a standardized instrument for measuring health outcomes in a wide range of health conditions and treatments. It consists of visual analogue scale (EQ VAS) which records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labeled 'Best imaginable health state' and 'worst imaginable health state'. The EQ VAS scores were anchored on 100 = the best health you can imagine and 0 = worst health you can imagine.

    Time frame: Baseline, Week 4, 8, 16, 28, 52, 80, 92, 104, 117, 130, 143, 156, 169, 182, 195, 208, 221, 234 and 247

  19. Change From Baseline in EQ-5D-5L VAS, by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover

    EQ-5D-5L is a standardized instrument for measuring health outcomes in a wide range of health conditions and treatments. It consists of visual analogue scale (EQ VAS) which records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labeled 'Best imaginable health state' and 'worst imaginable health state'. The EQ VAS scores were anchored on 100 = the best health you can imagine and 0 = worst health you can imagine.

    Time frame: Baseline (last assessment before cross over), Week 4, 8, 16, 24, 28, 52, 92, 104, 117, 130, 143, 156, 169, 182, 195, 208, 221, 234 and 247 after cross-over

  20. Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire

    The Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) is a six item questionnaire which intended to measure work and activity impairment associated with polycythemia vera. WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the polycythemia vera; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the polycythemia vera on productivity while working; Q6=Impact of the polycythemia vera on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. Scores were multiplied by 100 to express in percentages. Percent work time missed due to problem (past 7 days) =Q2/(Q2+Q4) Percent impairment while working due to problem (past 7 days): Q5/10 Percent overall work impairment due to problem (past 7 says): Q2/(Q2+Q4)+\[(1 Q2/(Q2+Q4))x(Q5/10)\] Percent activity impairment due to problem (past 7 says): Q6/10

    Time frame: Baseline, Week 4, 8, 16, 28, 52 and 80

  21. Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI), by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover

    The Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) is a six item questionnaire which intended to measure work and activity impairment associated with polycythemia vera. WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the polycythemia vera; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the polycythemia vera on productivity while working; Q6=Impact of the polycythemia vera on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. Scores were multiplied by 100 to express in percentages. Percent work time missed due to problem (past 7 days) =Q2/(Q2+Q4) Percent impairment while working due to problem (past 7 days): Q5/10 Percent overall work impairment due to problem (past 7 says): Q2/(Q2+Q4)+\[(1 Q2/(Q2+Q4))x(Q5/10)\] Percent activity impairment due to problem (past 7 says): Q6/10

    Time frame: Baseline (last assessment before cross over), Week 4, 8, 16, 24, 28 and 52 after cross-over

  22. Patient Global Impression of Change (PGIC)

    The Patient Global Impression of Change (PGIC) is comprised of a single question intended to measure a patient's perspective of improvement or deterioration over time relative to treatment. The PGIC uses a seven-point scale where one (1) equals very much improved and seven (7) equals very much worse.

    Time frame: Week 4, 8, 16, 28, 40, 52 and 80

  23. Summary of Patient Global Impression of Change (PGIC), by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover

    The Patient Global Impression of Change (PGIC) is comprised of a single question intended to measure a patient's perspective of improvement or deterioration over time relative to treatment. The PGIC uses a seven-point scale where one (1) equals very much improved and seven (7) equals very much worse.

    Time frame: Baseline (last assessment before cross over), Week 4, 8, 16, 24, 28, 40, and 52 after cross-over

  24. Number of Participants Developing Thrombosis

    Proportion of participants developing any arterial or venous thromboembolic event

    Time frame: From randomization to Week 80 for BAT and Week 260 for Ruxolitinib

07

Results

Posted Jul 20, 2021

Participant flow

Participants were randomized in 48 centers across 12 countries: Australia (1), Belgium (2), Canada (1), France (7), Germany (9), Hungary (3), India (2), Israel (3), Italy (7), South Korea (2), Spain (9) and Turkey (2)

Core Study
Participant flow — Core Study
MilestoneRuxolitinibBest Available Therapy (BAT)
Started7475
Full analysis set7475
Crossover set058
Completed5961
Not completed1514
Withdrew: Adverse event77
Withdrew: Death11
Withdrew: Disease progression22
Withdrew: Lost to follow-up01
Withdrew: Physician decision21
Withdrew: Subject/guardian decision01
Withdrew: Withdrawal by subject31
Crossover Period
Participant flow — Crossover Period
MilestoneRuxolitinibBest Available Therapy (BAT)
Started058
Completed038
Not completed020
Withdrew: Withdrawal by subject03
Withdrew: Adverse event09
Withdrew: Death02
Withdrew: Disease progression03
Withdrew: Lost to follow-up01
Withdrew: Physician decision02

Outcome measures

PrimaryNumber of Participants Achieving Hematocrit (Hct) Control at Week 28

Proportion of patients achieving Hct control at Week 28 was defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 28, with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8. Phlebotomy eligibility was defined by: * Confirmed Hct \> 45% that is at least 3 percentage points higher than the Hct obtained at Baseline Or * Confirmed Hct \> 48% The confirmation occurred 2 to 14 days subsequent to the initial observation.

Time frame:
Week 28
Reported as:
Count of participants · Participants
Number of Participants Achieving Hematocrit (Hct) Control at Week 28
ParticipantsRuxolitinibBest Available Therapy (BAT)
Number of Participants Achieving Hematocrit (Hct) Control at Week 284614
SecondaryNumber of Participants Achieving a Complete Hematological Remission at Week 28

Proportion of patients achieving a complete hematological remission at Week 28 was defined by: * Hct control at Week 28 defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 28, with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and * WBC \< 10 x109/L at Week 28, and * Platelets ≤ 400 x 109/L at Week 28

Time frame:
Week 28
Reported as:
Count of participants · Participants
Number of Participants Achieving a Complete Hematological Remission at Week 28
ParticipantsRuxolitinibBest Available Therapy (BAT)
Number of Participants Achieving a Complete Hematological Remission at Week 28174
SecondaryNumber of Participants Achieving a Hematocrit (Hct) Control at Week 52 and Week 80

Proportion of patients achieving a Hct control at Week 52 was defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 52, and no more than one phlebotomy eligibility occurring post randomization and prior to Week 8 - Endpoint for Week 80 was defined, similarly.

Time frame:
Week 52 and 80
Reported as:
Count of participants · Participants
Number of Participants Achieving a Hematocrit (Hct) Control at Week 52 and Week 80
ParticipantsRuxolitinibBest Available Therapy (BAT)
Week 52445
Week 80352
SecondaryNumber of Participants Achieving a Complete Hematological Remission at Week 52 and Week 80

Proportion of patients achieving a complete hematological remission at Week 52, was defined by: * Hct control at Week 52, as defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 52 with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and * White Blood Count (WBC) \< 10 x10\^9/L at Week 52, and * Platelets ≤ 400 x 10\^9/L at Week 52 * Endpoint for Week 80 was defined, similarly.

Time frame:
Week 52 and 80
Reported as:
Count of participants · Participants
Number of Participants Achieving a Complete Hematological Remission at Week 52 and Week 80
ParticipantsRuxolitinibBest Available Therapy (BAT)
Week 52173
Week 80182
SecondaryNumber of Participants With Phlebotomies Over Time

Phlebotomy eligibility was defined by Confirmed Hct \> 45% that is at least 3 percentage points higher than the Hct obtained at Baseline Or Confirmed Hct \> 48%. The confirmation occurred 2 to 14 days subsequent to the initial observation.

Time frame:
Baseline to Week 260
Reported as:
Count of participants · Participants
Number of Participants With Phlebotomies Over Time
ParticipantsRuxolitinibBest Available Therapy (BAT)
Phlebotomy frequency: >0 - <=21229
Phlebotomy frequency: >2 - <=4717
Phlebotomy frequency: >4 - <=642
Phlebotomy frequency: >6 - <=801
SecondaryChange From Baseline in Hematocrit (Hct) at Each Visit

Hematocrit is the volume percentage of red blood cells (RBC) in the blood.

Time frame:
Baseline, Week 4, 8, 12, 16, 20, 24, 28, 40, 52, 66, 80, 92, 104, 117, 130, 143, 156, 169, 182, 195, 208, 221, 234, 247 and 260
Reported as:
Mean · volume percentage of RBC in blood
Change From Baseline in Hematocrit (Hct) at Each Visit
volume percentage of RBC in bloodRuxolitinibBest Available Therapy (BAT)
Week 4-0.65 ± 2.9431.25 ± 2.994
Week 8-1.22 ± 3.6341.63 ± 3.344
Week 12-2.33 ± 4.5811.70 ± 3.485
Week 16-3.25 ± 4.1791.83 ± 3.439
Week 20-3.05 ± 4.3071.45 ± 3.984
Week 24-2.85 ± 4.0941.52 ± 2.934
Week 28-2.60 ± 4.1012.09 ± 3.852
Week 40-2.77 ± 4.5382.05 ± 4.587
Week 52-2.49 ± 4.4451.68 ± 4.854
Week 66-3.06 ± 4.5732.73 ± 2.922
Week 80-3.20 ± 3.8860.62 ± 4.436
Week 92-2.91 ± 4.203—
Week 104-3.19 ± 4.314—
Week 117-2.86 ± 4.540—
Week 130-3.13 ± 4.263—
Week 143-3.50 ± 3.463—
Week 156-3.54 ± 4.005—
Week 169-3.57 ± 4.477—
Week 182-2.94 ± 4.428—
Week 195-3.36 ± 4.515—
Week 208-3.23 ± 4.150—
Week 221-3.55 ± 4.413—
Week 234-3.31 ± 4.621—
Week 247-3.45 ± 4.053—
Week 260-2.93 ± 3.799—
SecondaryChange From Baseline in Hematocrit (Hct) at Each Scheduled Visit After Crossover in Participants Randomized to BAT Who Cross Over to Ruxolitinib

Hematocrit is the percentage of red blood cells (RBC) in the blood.

Time frame:
Baseline (last assessment before cross over), Week 4, 8, 12, 16, 20, 24, 28, 40, 52, 64, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206, 219 and 232 after cross-over
Reported as:
Mean · Volume percentage of RBC in blood
Change From Baseline in Hematocrit (Hct) at Each Scheduled Visit After Crossover in Participants Randomized to BAT Who Cross Over to Ruxolitinib
Volume percentage of RBC in bloodAll Crossover Patients
Week +4-2.44 ± 3.394
Week +8-4.24 ± 5.322
Week +12-5.73 ± 6.597
Week +16-6.27 ± 7.101
Week +20-5.76 ± 6.563
Week +24-5.29 ± 6.518
Week +28-6.04 ± 5.825
Week +40-6.06 ± 6.301
Week +52-5.91 ± 6.399
Week +64-7.06 ± 6.051
Week +76-6.16 ± 6.247
Week +89-6.79 ± 6.046
Week +102-6.21 ± 6.599
Week +115-7.04 ± 6.103
Week +128-7.41 ± 6.812
Week +141-7.00 ± 6.310
Week +154-7.06 ± 7.000
Week +167-7.44 ± 7.426
Week +180-7.51 ± 7.298
Week +193-7.16 ± 5.331
Week +206-7.09 ± 5.742
Week +219-6.95 ± 5.936
Week +232-7.51 ± 5.880
SecondarySpleen Length by Visit

Spleen length was assessed by manual palpation at every study visit.

Time frame:
Week 4, 8, 12, 16, 20, 24, 28, 40, 52, 66, 80, 92, 104, 117, 130, 143, 156, 169, 182, 195, 208, 221, 234, 247 and 260
Reported as:
Mean · cm
Spleen Length by Visit
cmRuxolitinibBest Available Therapy (BAT)
Week 40.00 ± 0.0000.04 ± 0.351
Week 80.00 ± 0.0000.01 ± 0.119
Week 120.00 ± 0.0000.01 ± 0.120
Week 160.00 ± 0.0000.23 ± 1.010
Week 200.00 ± 0.0000.13 ± 0.716
Week 240.00 ± 0.0000.09 ± 0.555
Week 280.00 ± 0.0000.20 ± 0.909
Week 400.01 ± 0.1200.52 ± 1.473
Week 520.06 ± 0.4820.07 ± 0.258
Week 660.00 ± 0.0000.00 ± 0.000
Week 800.03 ± 0.2460.00 ± 0.000
Week 920.00 ± 0.000—
Week 1040.05 ± 0.378—
Week 1170.12 ± 0.985—
Week 1300.18 ± 1.162—
Week 1430.08 ± 0.458—
Week 1560.05 ± 0.372—
Week 1690.05 ± 0.378—
Week 1820.05 ± 0.381—
Week 1950.00 ± 0.000—
Week 2080.00 ± 0.000—
Week 2210.02 ± 0.129—
Week 2340.00 ± 0.000—
Week 2470.02 ± 0.136—
Week 2600.10 ± 0.617—
SecondaryChange From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status to Week 28

The ECOG scale of performance status described the level of functioning of participants in terms of their ability to care for themselves, daily activity, and physical ability. The ECOG performance was recorded as per ECOG performance status grades ranging from 0 (fully active, able to carry on all pre-disease performance without restriction) to 5 (dead).

Time frame:
Baseline and Week 28
Reported as:
Count of participants · Participants
Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status to Week 28
ParticipantsRuxolitinibBest Available Therapy (BAT)
Grade 0 at baseline — 0: Fully active, able to carry on all pre-disease performance without restriction4917
Grade 0 at baseline — 1: Restricted in physically strenuous activity and able to carry out light or sedentary work21
Grade 0 at baseline — 2: Ambulatory and capable of all self-care but unable to carry out any work activities00
Grade 0 at baseline — 3: Capable of only limited self-care, confined to bed or chair more than 50% of waking hours00
Grade 0 at baseline — 4: Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair00
Grade 0 at baseline — Missing238
Grade 1 at baseline — 0: Fully active, able to carry on all pre-disease performance without restriction91
Grade 1 at baseline — 1: Restricted in physically strenuous activity and able to carry out light or sedentary work105
Grade 1 at baseline — 2: Ambulatory and capable of all self-care but unable to carry out any work activities10
Grade 1 at baseline — 3: Capable of only limited self-care, confined to bed or chair more than 50% of waking hours00
Grade 1 at baseline — 4: Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair00
Grade 1 at baseline — Missing113
SecondaryNumber of Participants Achieving a Partial Remission Based on the European Leukemia Net (ELN) and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Criteria at Week 28

Proportion of patients achieving a partial remission at Week 28, based on the ELN and IWG-MRT criteria, as defined by: * Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) score reduction of greater than or equal to 10 points from baseline to Week 28, and * Hct control defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 28, with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and * WBC \< 10 x10\^9/L at Week 28, and * Platelets ≤ 400 x 10\^9/L at Week 28, and * No palpable spleen at Week 28, and * No hemorrhagic or thrombotic events, and * No transformation into post-PV myelofibrosis, myelodysplastic syndrome (IWG-MRT criteria) or acute leukemia (WHO criteria).

Time frame:
Week 28
Reported as:
Count of participants · Participants
Number of Participants Achieving a Partial Remission Based on the European Leukemia Net (ELN) and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Criteria at Week 28
ParticipantsRuxolitinibBest Available Therapy (BAT)
Number of Participants Achieving a Partial Remission Based on the European Leukemia Net (ELN) and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Criteria at Week 2870
SecondaryNumber of Participants Who Achieved Partial Remission Based on the European Leukemia Net (ELN) and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Criteria at Week 52 and Week 80

Proportion of patients who achieved partial remission at Week 52 based on the ELN and IWG-MRT criteria, as defined by: * MPN-SAF TSS score reduction of greater than or equal to 10 points from baseline to Week 52 and * Hct control defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 52 with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and * WBC \< 10 x109/L at Week 52 and * Platelets ≤ 400 x 109/L at Week 52 and * No palpable spleen at Week 52 and * No hemorrhagic or thrombotic events, and * No transformation into post-PV myelofibrosis, myelodysplastic syndrome (IWG-MRT criteria) or acute leukemia (WHO criteria). * Endpoint for Week 80 was defined, similarly.

Time frame:
Week 52 and 80
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Partial Remission Based on the European Leukemia Net (ELN) and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Criteria at Week 52 and Week 80
ParticipantsRuxolitinibBest Available Therapy (BAT)
Week 5250
Week 8040
SecondaryNumber of Participants Achieving a Hematocrit (Hct) Control at Week 104, Week 156, Week 208 and Week 260.

Proportion of patients achieving a Hct control at Week 104 as defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 104 and with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8 Endpoint for Week 156, Week 208 and Week 260 were defined, similarly.

Time frame:
From Week 8 to Week 104, 156, 208 and 260
Reported as:
Count of participants · Participants
Number of Participants Achieving a Hematocrit (Hct) Control at Week 104, Week 156, Week 208 and Week 260.
ParticipantsRuxolitinib
Week 104 — HU Resistant9
Week 104 — HU Intolerant25
Week 156 — HU Resistant9
Week 156 — HU Intolerant21
Week 208 — HU Resistant7
Week 208 — HU Intolerant18
Week 260 — HU Resistant4
Week 260 — HU Intolerant12
SecondaryNumber of Participants Achieving a Complete Hematological Remission at Week 104, Week 156, Week 208 and Week 260

Proportion of patients achieving a complete hematological remission at Week 104 as defined by Hct control defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 104, with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and * WBC \< 10 x10\^9/L at Week 104, and * Platelets ≤ 400 x 10\^9/L at Week 104 Endpoint for Week 156, Week 208 and Week 260 were defined, similarly.

Time frame:
From Week 8 to Week 104, 156, 208 and 260
Reported as:
Count of participants · Participants
Number of Participants Achieving a Complete Hematological Remission at Week 104, Week 156, Week 208 and Week 260
ParticipantsRuxolitinib
Week 10415
Week 15619
Week 20811
Week 2609
SecondaryNumber of Participants Who Achieved Partial Remission Based on the European Leukemia Net (ELN) and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Criteria at Week 104, Week 156, Week 208 and Week 260.

Proportion of patients who achieved partial remission at Week 104, based on the ELN and IWG-MRT criteria, as defined by: * MPN-SAF TSS score reduction of greater than or equal to 10 points from baseline to Week 104, and * Hct control defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 104, with no more than one phlebotomy eligibility occurring post-randomization and prior to Week 8, and * WBC \< 10 x10\^9/L at Week 104, and * Platelets ≤ 400 x 10\^9/L at Week 104, and * No palpable spleen at Week 104, and * No hemorrhagic or thrombotic events, and * No transformation into post-PV myelofibrosis, myelodysplastic syndrome (IWG-MRT criteria) or acute leukemia (WHO criteria) Endpoint for Week 156, Week 208 and Week 260 are defined, similarly.

Time frame:
From Week 8 to Week 104, 156, 208 and 260
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Partial Remission Based on the European Leukemia Net (ELN) and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Criteria at Week 104, Week 156, Week 208 and Week 260.
ParticipantsRuxolitinib
Week 1044
Week 1569
Week 2084
Week 2600
SecondaryNumber of Participants With Transformation Free Survival Events

Transformation-free survival is defined as one of the following: 1. Myelofibrosis (MF) as evidenced by bone marrow biopsy, or 2. Acute leukemia as evidenced by bone marrow blast counts of at least 20%, or peripheral blast counts of at least 20% lasting at least 2 weeks. 3. Death due to any cause during treatment period

Time frame:
Week 260 (ruxolitinib arm) and Week 80 (BAT arm)
Reported as:
Count of participants · Participants
Number of Participants With Transformation Free Survival Events
ParticipantsRuxolitinibBest Available Therapy (BAT)
Number of Participants With Transformation Free Survival Events43
SecondaryNumber of Participants With Overall Survival (OS) Events

Overall survival (OS) event is defined as death due to any cause. OS events were counted in the BAT arm, irrespective of whether participants crossed over to receive ruxolitinib when the event occurred.

Time frame:
up to Week 260
Reported as:
Count of participants · Participants
Number of Participants With Overall Survival (OS) Events
ParticipantsRuxolitinibBest Available Therapy (BAT)
Number of Participants With Overall Survival (OS) Events36
SecondaryChange From Baseline in Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)

The MPN-SAF TSS is a disease specific questionnaire comprised of 10 items that measures fatigue related to MPN disease and the severity of nine of the most prevalent associated symptoms. Each item is scored on a scale ranging from 0 (no fatigue/absent) to 10 (As bad as you can imagine/worst imaginable).The MPN-SAF TSS is computed as the average of the observed items multiplied by 10 to achieve a 0-to-100 scale. The MPN-SAF TSS thus has a possible score range of 0 to 100 where a decrease indicates improvement.

Time frame:
Baseline, Week 4, 8, 16, 28, 40, 52, 80, 92, 104, 117, 130, 143, 156, 169, 182, 195, 208, 221, 234 and 247
Reported as:
Mean · Score on a scale
Change From Baseline in Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)
Score on a scaleRuxolitinibBest Available Therapy (BAT)
Week 4-8.43 ± 12.3410.40 ± 12.586
Week 8-9.86 ± 12.2101.37 ± 12.046
Week 16-9.14 ± 13.9801.41 ± 10.760
Week 28-10.29 ± 14.2042.34 ± 13.047
Week 40-9.35 ± 14.0270.10 ± 9.586
Week 52-8.63 ± 13.4030.63 ± 9.334
Week 80-9.04 ± 13.520—
Week 92-7.69 ± 11.971—
Week 104-6.82 ± 13.297—
Week 117-6.76 ± 13.702—
Week 130-8.26 ± 16.234—
Week 143-8.56 ± 15.653—
Week 156-8.48 ± 15.081—
Week 169-7.65 ± 14.392—
Week 182-9.34 ± 14.675—
Week 195-7.57 ± 14.922—
Week 208-9.26 ± 16.347—
Week 221-7.20 ± 16.054—
Week 234-7.50 ± 15.922—
Week 247-7.82 ± 16.905—
SecondaryChange From Baseline in Total Scores of MPN-SAF by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover

The MPN-SAF TSS is a disease specific questionnaire comprised of 10 items that measures fatigue related to MPN disease and the severity of nine of the most prevalent associated symptoms. Each item is scored on a scale ranging from 0 (no fatigue/absent) to 10 (As bad as you can imagine/worst imaginable).The MPN-SAF TSS is computed as the average of the observed items multiplied by 10 to achieve a 0-to-100 scale. The MPN-SAF TSS thus has a possible score range of 0 to 100 where a decrease indicates improvement.

Time frame:
Baseline (last assessment before cross over), Week 4, 8, 16, 24, 28, 40, 52, 92, 104, 117, 130, 143, 156, 169, 182, 195, 208, 221, 234 and 247 after cross-over
Reported as:
Mean · Score on a scale
Change From Baseline in Total Scores of MPN-SAF by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover
Score on a scaleBest Available Therapy (BAT)
Week +4-8.00 ± 10.532
Week +8-9.76 ± 11.543
Week +16-9.40 ± 12.040
Week +24-9.15 ± 12.738
Week +28-8.46 ± 12.212
Week +40-8.58 ± 13.302
Week +52-7.15 ± 14.392
Week 92-10.49 ± 13.902
Week 104-8.08 ± 16.288
Week 117-9.01 ± 14.708
Week 130-10.18 ± 15.740
Week 143-8.36 ± 17.030
Week 156-9.54 ± 14.573
Week 169-11.15 ± 14.305
Week 182-10.13 ± 16.113
Week 195-10.88 ± 14.357
Week 208-9.43 ± 15.360
Week 221-10.02 ± 15.986
Week 234-8.01 ± 14.404
Week 247-9.84 ± 14.979
SecondaryChange From Baseline in Score as Per European Quality of Life 5-Dimension 5-level (EQ-5D-5L) Questionnaire

EQ-5D-5L is a standardized instrument for measuring health outcomes in a wide range of health conditions and treatments. It consists of visual analogue scale (EQ VAS) which records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labeled 'Best imaginable health state' and 'worst imaginable health state'. The EQ VAS scores were anchored on 100 = the best health you can imagine and 0 = worst health you can imagine.

Time frame:
Baseline, Week 4, 8, 16, 28, 52, 80, 92, 104, 117, 130, 143, 156, 169, 182, 195, 208, 221, 234 and 247
Reported as:
Mean · Score on a scale
Change From Baseline in Score as Per European Quality of Life 5-Dimension 5-level (EQ-5D-5L) Questionnaire
Score on a scaleRuxolitinibBest Available Therapy (BAT)
Week 44.24 ± 11.6610.04 ± 18.323
Week 87.62 ± 14.846-2.73 ± 16.097
Week 166.35 ± 17.946-3.12 ± 14.435
Week 287.56 ± 14.3090.16 ± 15.201
Week 527.36 ± 13.9962.50 ± 10.697
Week 804.50 ± 18.273—
Week 926.77 ± 18.948—
Week 1046.25 ± 18.143—
Week 1176.42 ± 15.130—
Week 1307.70 ± 16.488—
Week 1435.68 ± 17.332—
Week 1564.74 ± 19.032—
Week 1696.08 ± 18.717—
Week 1827.68 ± 17.992—
Week 1956.41 ± 18.239—
Week 2087.94 ± 18.614—
Week 2213.64 ± 19.866—
Week 2345.48 ± 18.625—
Week 2476.28 ± 17.854—
SecondaryChange From Baseline in EQ-5D-5L VAS, by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover

EQ-5D-5L is a standardized instrument for measuring health outcomes in a wide range of health conditions and treatments. It consists of visual analogue scale (EQ VAS) which records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labeled 'Best imaginable health state' and 'worst imaginable health state'. The EQ VAS scores were anchored on 100 = the best health you can imagine and 0 = worst health you can imagine.

Time frame:
Baseline (last assessment before cross over), Week 4, 8, 16, 24, 28, 52, 92, 104, 117, 130, 143, 156, 169, 182, 195, 208, 221, 234 and 247 after cross-over
Reported as:
Mean · Score on a scale
Change From Baseline in EQ-5D-5L VAS, by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover
Score on a scaleBest Available Therapy (BAT)
Week +44.54 ± 14.756
Week +84.62 ± 15.807
Week +166.58 ± 14.667
Week +246.38 ± 17.564
Week +285.26 ± 15.923
Week +524.71 ± 21.006
Week 928.09 ± 16.119
Week 1046.48 ± 18.085
Week 1174.92 ± 16.983
Week 1304.87 ± 20.047
Week 1433.19 ± 17.798
Week 1562.65 ± 20.221
Week 1694.59 ± 13.731
Week 1822.71 ± 19.673
Week 1955.65 ± 18.286
Week 2085.35 ± 18.099
Week 2217.71 ± 16.701
Week 2345.30 ± 18.342
Week 2474.14 ± 16.427
SecondaryChange From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire

The Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) is a six item questionnaire which intended to measure work and activity impairment associated with polycythemia vera. WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the polycythemia vera; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the polycythemia vera on productivity while working; Q6=Impact of the polycythemia vera on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. Scores were multiplied by 100 to express in percentages. Percent work time missed due to problem (past 7 days) =Q2/(Q2+Q4) Percent impairment while working due to problem (past 7 days): Q5/10 Percent overall work impairment due to problem (past 7 says): Q2/(Q2+Q4)+\[(1 Q2/(Q2+Q4))x(Q5/10)\] Percent activity impairment due to problem (past 7 says): Q6/10

Time frame:
Baseline, Week 4, 8, 16, 28, 52 and 80
Reported as:
Mean · Percent
Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire
PercentRuxolitinibBest Available Therapy (BAT)
Percent work time missed due to problem (past 7 days) Week 4-5.50 ± 18.425-0.40 ± 13.928
Percent work time missed due to problem (past 7 days) Week 8-4.88 ± 13.381-4.35 ± 20.820
Percent work time missed due to problem (past 7 days) Week 164.50 ± 35.9484.79 ± 25.917
Percent work time missed due to problem (past 7 days) Week 28-5.85 ± 17.119-2.19 ± 9.852
Percent work time missed due to problem (past 7 days) Week 52-2.82 ± 30.770-8.33 ± 11.785
Percent work time missed due to problem (past 7 days) Week 801.87 ± 34.151—
Percent impairment while working due to problem (past 7 days) Week 4-6.67 ± 23.3100.00 ± 14.951
Percent impairment while working due to problem (past 7 days) Week 8-13.16 ± 19.164-0.59 ± 13.449
Percent impairment while working due to problem (past 7 days) Week 16-14.00 ± 21.3744.12 ± 16.977
Percent impairment while working due to problem (past 7 days) Week 28-14.29 ± 23.994-10.00 ± 14.142
Percent impairment while working due to problem (past 7 days) Week 52-10.00 ± 23.170-20.00 ± 42.426
Percent impairment while working due to problem (past 7 days) Week 80-14.76 ± 26.385—
Percent overall work impairment due to problem (past 7 days) Week 4-9.63 ± 22.495-2.34 ± 14.807
Percent overall work impairment due to problem (past 7 days) Week 8-11.32 ± 18.505-4.38 ± 17.568
Percent overall work impairment due to problem (past 7 days) Week 16-10.26 ± 33.2965.34 ± 22.063
Percent overall work impairment due to problem (past 7 days) Week 28-15.98 ± 23.077-8.85 ± 11.722
Percent overall work impairment due to problem (past 7 days) Week 52-12.61 ± 27.576-22.50 ± 45.962
Percent overall work impairment due to problem (past 7 days) Week 80-14.36 ± 30.691—
Percent activity impairment due to problem (past 7 days) Week 4-11.97 ± 22.1222.42 ± 24.310
Percent activity impairment due to problem (past 7 days) Week 8-11.58 ± 24.9851.97 ± 16.413
Percent activity impairment due to problem (past 7 days) Week 16-14.36 ± 25.2220.65 ± 18.980
Percent activity impairment due to problem (past 7 days) Week 28-11.67 ± 25.8262.73 ± 23.941
Percent activity impairment due to problem (past 7 days) Week 52-11.23 ± 25.3600.00 ± 15.374
Percent activity impairment due to problem (past 7 days) Week 80-11.09 ± 24.166—
SecondaryChange From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI), by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover

The Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) is a six item questionnaire which intended to measure work and activity impairment associated with polycythemia vera. WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the polycythemia vera; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the polycythemia vera on productivity while working; Q6=Impact of the polycythemia vera on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. Scores were multiplied by 100 to express in percentages. Percent work time missed due to problem (past 7 days) =Q2/(Q2+Q4) Percent impairment while working due to problem (past 7 days): Q5/10 Percent overall work impairment due to problem (past 7 says): Q2/(Q2+Q4)+\[(1 Q2/(Q2+Q4))x(Q5/10)\] Percent activity impairment due to problem (past 7 says): Q6/10

Time frame:
Baseline (last assessment before cross over), Week 4, 8, 16, 24, 28 and 52 after cross-over
Reported as:
Mean · Percent
Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI), by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover
PercentBest Available Therapy (BAT)
Percent work time missed due to problem (past 7 days) Week +4-7.45 ± 28.102
Percent work time missed due to problem (past 7 days) Week +8-3.90 ± 33.237
Percent work time missed due to problem (past 7 days) Week +16-2.66 ± 40.422
Percent work time missed due to problem (past 7 days) Week +24-1.67 ± 5.000
Percent work time missed due to problem (past 7 days) Week +287.06 ± 21.757
Percent work time missed due to problem (past 7 days) Week +521.12 ± 3.175
Percent impairment while working due to problem (past 7 days) Week +4-5.33 ± 9.904
Percent impairment while working due to problem (past 7 days) Week +8-4.29 ± 11.579
Percent impairment while working due to problem (past 7 days) Week +16-10.83 ± 20.207
Percent impairment while working due to problem (past 7 days) Week +24-6.92 ± 13.156
Percent impairment while working due to problem (past 7 days) Week +28-3.33 ± 23.868
Percent impairment while working due to problem (past 7 days) Week +52-6.00 ± 13.499
Percent overall work impairment due to problem (past 7 days) Week +4-10.98 ± 20.249
Percent overall work impairment due to problem (past 7 days) Week +8-6.91 ± 24.416
Percent overall work impairment due to problem (past 7 days) Week +16-4.73 ± 30.167
Percent overall work impairment due to problem (past 7 days) Week +24-6.06 ± 14.099
Percent overall work impairment due to problem (past 7 days) Week +28-1.81 ± 20.220
Percent overall work impairment due to problem (past 7 days) Week +52-4.03 ± 12.712
Percent activity impairment due to problem (past 7 days) Week +4-10.43 ± 19.886
Percent activity impairment due to problem (past 7 days) Week +8-8.63 ± 20.978
Percent activity impairment due to problem (past 7 days) Week +16-8.82 ± 21.877
Percent activity impairment due to problem (past 7 days) Week +24-6.47 ± 25.363
Percent activity impairment due to problem (past 7 days) Week +28-6.94 ± 26.395
Percent activity impairment due to problem (past 7 days) Week +52-7.00 ± 22.781
SecondaryPatient Global Impression of Change (PGIC)

The Patient Global Impression of Change (PGIC) is comprised of a single question intended to measure a patient's perspective of improvement or deterioration over time relative to treatment. The PGIC uses a seven-point scale where one (1) equals very much improved and seven (7) equals very much worse.

Time frame:
Week 4, 8, 16, 28, 40, 52 and 80
Reported as:
Count of participants · Participants
Patient Global Impression of Change (PGIC)
ParticipantsRuxolitinibBest Available Therapy (BAT)
Week 4 — Very much improved100
Week 4 — Much improved228
Week 4 — Minimally improved217
Week 4 — No change1450
Week 4 — Minimally worse16
Week 4 — Much worse00
Week 4 — Very much worse01
Week 8 — Very much improved111
Week 8 — Much improved2714
Week 8 — Minimally improved159
Week 8 — No change1535
Week 8 — Minimally worse010
Week 8 — Much worse10
Week 8 — Very much worse01
Week 16 — Very much improved182
Week 16 — Much improved2513
Week 16 — Minimally improved1312
Week 16 — No change833
Week 16 — Minimally worse24
Week 16 — Much worse05
Week 16 — Very much worse00
Week 28 — Very much improved190
Week 28 — Much improved254
Week 28 — Minimally improved125
Week 28 — No change915
Week 28 — Minimally worse13
Week 28 — Much worse00
Week 28 — Very much worse00
Week 40 — Very much improved230
Week 40 — Much improved307
Week 40 — Minimally improved52
Week 40 — No change610
Week 40 — Minimally worse20
Week 40 — Much worse00
Week 40 — Very much worse00
Week 52 — Very much improved272
Week 52 — Much improved285
Week 52 — Minimally improved81
Week 52 — No change55
Week 52 — Minimally worse21
Week 52 — Much worse00
Week 52 — Very much worse00
Week 66 — Very much improved231
Week 66 — Much improved311
Week 66 — Minimally improved63
Week 66 — No change60
Week 66 — Minimally worse10
Week 66 — Much worse00
Week 66 — Very much worse00
Week 80 — Very much improved220
Week 80 — Much improved240
Week 80 — Minimally improved90
Week 80 — No change100
Week 80 — Minimally worse20
Week 80 — Much worse00
Week 80 — Very much worse10
SecondarySummary of Patient Global Impression of Change (PGIC), by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover

The Patient Global Impression of Change (PGIC) is comprised of a single question intended to measure a patient's perspective of improvement or deterioration over time relative to treatment. The PGIC uses a seven-point scale where one (1) equals very much improved and seven (7) equals very much worse.

Time frame:
Baseline (last assessment before cross over), Week 4, 8, 16, 24, 28, 40, and 52 after cross-over
Reported as:
Count of participants · Participants
Summary of Patient Global Impression of Change (PGIC), by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover
ParticipantsBest Available Therapy (BAT)
Week +4 — Very much improved10
Week +4 — Much improved13
Week +4 — Minimally improved13
Week +4 — No change16
Week +4 — Minimally worse0
Week +4 — Much worse0
Week +8 — Very much improved11
Week +8 — Much improved25
Week +8 — Minimally improved9
Week +8 — No change7
Week +8 — Minimally worse1
Week +8 — Much worse0
Week +16 — Very much improved12
Week +16 — Much improved28
Week +16 — Minimally improved6
Week +16 — No change6
Week +16 — Minimally worse0
Week +16 — Much worse0
Week +24 — Very much improved19
Week +24 — Much improved17
Week +24 — Minimally improved5
Week +24 — No change8
Week +24 — Minimally worse1
Week +24 — Much worse0
Week +28 — Very much improved18
Week +28 — Much improved19
Week +28 — Minimally improved6
Week +28 — No change6
Week +28 — Minimally worse1
Week +28 — Much worse0
Week +40 — Very much improved18
Week +40 — Much improved15
Week +40 — Minimally improved5
Week +40 — No change6
Week +40 — Minimally worse0
Week +40 — Much worse0
Week +52 — Very much improved17
Week +52 — Much improved16
Week +52 — Minimally improved6
Week +52 — No change3
Week +52 — Minimally worse0
Week +52 — Much worse0
SecondaryNumber of Participants Developing Thrombosis

Proportion of participants developing any arterial or venous thromboembolic event

Time frame:
From randomization to Week 80 for BAT and Week 260 for Ruxolitinib
Reported as:
Count of participants · Participants
Number of Participants Developing Thrombosis
ParticipantsRuxolitinibBest Available Therapy (BAT)
Number of Participants Developing Thrombosis00
Post-hocTotal Number of Deaths

On-treatment deaths were reported from the day of first dose of study medication to the End of study (End of Treatment +30 days) visit which was Week 260 or prior (+30 days for Rux + crossover) and Week 80 or prior (+30 days for BAT only). Post-treatment deaths were reported following completion study treatment (Week 80 for patients receiving BAT, or Week 260 for patients receiving ruxolitinib) or from the time of premature discontinuation. Patients were followed for survival every three months up to end of study.

Time frame:
Up to Week 260
Reported as:
Number · Participants
Total Number of Deaths
ParticipantsRuxolitinibBest Available Therapy (BAT)
Death occurring up to 30 days after end of randomised treatment.11
Death occurring among patients who died after cross over to ruxolitinib (BAT arm only).03
Death occurring more than 30 days after end of treatment.22

Adverse events

Collected over Adverse events were collected from the day of first dose of study medication to the End of study (End of Treatment +30 days) visit which was Week 260 or prior (+30 days for Rux + crossover) and Week 80 or prior (+30 days for BAT only).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ruxolitinib1/74 (1.4%)34/74 (45.9%)73/74 (98.6%)
Best Available Therapy1/75 (1.3%)9/75 (12%)56/75 (74.7%)
All Crossover Patients3/58 (5.2%)23/58 (39.7%)56/58 (96.6%)
Most frequent serious events
Showing 10 of 125
Most frequent serious events
EventRuxolitinibBest Available TherapyAll Crossover Patients
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/740/751/58
OsteoarthritisMusculoskeletal and connective tissue disorders2/740/753/58
BronchitisInfections and infestations3/740/750/58
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/740/751/58
AstheniaGeneral disorders0/740/752/58
PneumoniaInfections and infestations0/741/752/58
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/740/752/58
Angina pectorisCardiac disorders2/740/750/58
Atrial fibrillationCardiac disorders2/741/751/58
Urinary tract infectionInfections and infestations2/740/750/58
Most frequent other events
Showing 10 of 65
Most frequent other events
EventRuxolitinibBest Available TherapyAll Crossover Patients
AnaemiaBlood and lymphatic system disorders27/741/7519/58
ArthralgiaMusculoskeletal and connective tissue disorders20/743/756/58
Weight increasedInvestigations19/741/759/58
PruritusSkin and subcutaneous tissue disorders12/7417/757/58
HypertensionVascular disorders15/743/7511/58
ConstipationGastrointestinal disorders13/744/758/58
FatigueGeneral disorders13/746/756/58
PyrexiaGeneral disorders13/741/757/58
HeadacheNervous system disorders13/749/758/58
NasopharyngitisInfections and infestations8/742/7510/58

Baseline characteristics

Age, Continuous
Age, Continuous(years)RuxolitinibBest Available Therapy (BAT)Total
Mean62.8 ± 11.3166.0 ± 11.1264.4 ± 11.29
Sex: Female, Male
Sex: Female, Male(Participants)RuxolitinibBest Available Therapy (BAT)Total
Female352863
Male394786
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RuxolitinibBest Available Therapy (BAT)Total
Caucasian6766133
Asian459
Other347
08

Study locations

48 sites
  • Novartis Investigative Site
    Herston, Queensland 4029, Australia
  • Novartis Investigative Site
    Antwerpen, 2060, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Toronto, Ontario M4N 3M5, Canada
  • Novartis Investigative Site
    Bayonne, Bayonne Cedex 64109, France
  • Novartis Investigative Site
    Bordeaux, 33076, France
  • Novartis Investigative Site
    Brest, 29200, France
  • Novartis Investigative Site
    Lille cedex, 59020, France
  • Novartis Investigative Site
    Nice Cedex, 06202, France
  • Novartis Investigative Site
    Paris, 75010, France
  • Novartis Investigative Site
    Toulouse, 31059, France
  • Novartis Investigative Site
    Mannheim, Baden-Wuerttemberg 68305, Germany
  • Novartis Investigative Site
    Augsburg, 86150, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Jena, 07740, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Magdeburg, 39120, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Minden, 32429, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Budapest, 1085, Hungary
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Kaposvar, 7400, Hungary
  • Novartis Investigative Site
    Mumbai, Maharashtra 400012, India
  • Novartis Investigative Site
    Vellore, Tamil Nadu 632 004, India
  • Novartis Investigative Site
    Nahariya, 22100, Israel
  • Novartis Investigative Site
    Netanya, 42150, Israel
  • Novartis Investigative Site
    Tel Aviv, 6423906, Israel
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Firenze, FI 50134, Italy
  • Novartis Investigative Site
    Roma, Lazio 00168, Italy
  • Novartis Investigative Site
    Milano, MI 20122, Italy
  • Novartis Investigative Site
    Pavia, PV 27100, Italy
  • Novartis Investigative Site
    Torino, TO 10126, Italy
  • Novartis Investigative Site
    Varese, VA 21100, Italy
  • Novartis Investigative Site
    Seoul, 03080, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 03722, Korea, Republic of
  • Novartis Investigative Site
    Malaga, Andalucia 29010, Spain
  • Novartis Investigative Site
    Salamanca, Castilla Y Leon 37007, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Alicante, Comunidad Valenciana 03010, Spain
  • Novartis Investigative Site
    La Coruna, Galicia 15006, Spain
  • Novartis Investigative Site
    Las Palmas de Gran Canaria, Las Palmas De G.C 35010, Spain
  • Novartis Investigative Site
    Pamplona, Navarra 31008, Spain
  • Novartis Investigative Site
    Madrid, 28034, Spain
  • Novartis Investigative Site
    Madrid, 28046, Spain
  • Novartis Investigative Site
    Izmir, 35040, Turkey
  • Novartis Investigative Site
    Talas / Kayseri, 38039, Turkey
09

References and documents

Publications

  • Passamonti F, Palandri F, Saydam G, Callum J, Devos T, Guglielmelli P, Vannucchi AM, Zor E, Zuurman M, Gilotti G, Zhang Y, Griesshammer M. Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. Lancet Haematol. 2022 Jul;9(7):e480-e492. doi: 10.1016/S2352-3026(22)00102-8. Epub 2022 May 18. PubMed 35597252 ↗
  • Kiladjian JJ, Guglielmelli P, Griesshammer M, Saydam G, Masszi T, Durrant S, Passamonti F, Jones M, Zhen H, Li J, Gadbaw B, Perez Ronco J, Khan M, Verstovsek S. Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. Ann Hematol. 2018 Apr;97(4):617-627. doi: 10.1007/s00277-017-3225-1. Epub 2018 Feb 2. PubMed 29396713 ↗
  • Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, Callum J, Vannucchi AM, Sivgin S, Bensasson C, Khan M, Mounedji N, Saydam G. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol. 2017 Jan;18(1):88-99. doi: 10.1016/S1470-2045(16)30558-7. Epub 2016 Dec 2. PubMed 27916398 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2014 to primary completion in Sep 2015, 18 months.

Results were first posted in Jul 2021, 5 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2014
First posted
Jan 16, 2014
StartActual
Mar 25, 2014
Primary completionActual
Sep 29, 2015
CompletionActual
Apr 7, 2020
Results first posted
Jul 20, 2021
Last update
Jul 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02038036
Responsible party
Sponsor
First posted
Jan 16, 2014
Start date
Mar 25, 2014
Primary completion
Sep 29, 2015
Completion
Apr 7, 2020
Results posted
Jul 20, 2021
Last update
Jul 20, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion